Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab-based combinations for unresectable inflammatory myofibroblastic tumor
ChiCTR2200056173Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab, crizotinib and Rivoceranib in inflammatory pseudotumor (IPT) (2 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: objective response rate. Started Jan 2022; status: recruiting.
02
Drugs
camrelizumabcrizotinibRivoceranib
03
Conditions
inflammatory pseudotumor (IPT)
Beyond the preview
Go deeper on ChiCTR2200056173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056173.